Frank E. Thomas - 17 Aug 2021 Form 4 Insider Report for Spero Therapeutics, Inc. (SPRO)

Reporting relationship: Director
Issuer ticker: SPRO
Reported as of: 17 Aug 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Aug 2021, 16:55:51 UTC
Prior SEC filing: 17 May 2021
Next SEC filing: 07 Jan 2022
Source filing: View source filing
Reporting owner signature: /s/ Matthew J. Gardella, as Attorney-in-Fact for Frank E. Thomas

Key filing fact

Frank E. Thomas filed Form 4 for Spero Therapeutics, Inc. (SPRO) on 18 Aug 2021.

Key facts

This page summarizes Frank E. Thomas's Form 4 filing for Spero Therapeutics, Inc. (SPRO).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 18 Aug 2021, 16:55.

Change

Previous filing in this sequence was filed on 17 May 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SPRO transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +7,500
Change %
Price: $0.000000
Shares after: 7,500
Date: 17 Aug 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,500
Exercise price: $13.69
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares underlying this option will vest and become exercisable in full on August 17, 2022 subject to the Reporting Person's continued service as a director through the vesting date.